# New Clinical Guidance Released for Managing Menopause Symptoms Updated medical advice highlights diverse hormonal and nonhormonal treatment options for menopausal women. - **Source:** [Sci-Tech News | Latest Technological Developments | The Hindu](https://www.thehindu.com/sci-tech/) - **Published:** 2026-11-01 - **Topic:** [Business](https://brifing.si/c/business) - **Original article:** - **On Brifing:** https://brifing.si/s/fd9462dd-5da6-4ef6-ae69-e85d5fa22a31 ## Updated Clinical Guidelines The American College of Obstetricians and Gynecologists has released its first updated guidance in twelve years regarding menopause management. This new framework addresses disruptive symptoms like hot flashes, night sweats, and sleep disturbances. The organization aims to empower patients to advocate for effective treatments after years of systemic medical hesitation. ## Hormone Therapy Revival Medical professionals now emphasize hormone therapy as the primary treatment for moderate to severe menopausal symptoms. This shift follows the FDA's decision to remove boxed safety warnings from over twenty estrogen and progestin products. These warnings, present for twenty-two years, had previously discouraged both doctors and patients from utilizing these therapies. ## Supply Chain Dynamics Following the removal of federal warnings, demand for hormone-based treatments has surged significantly across the United States. While some patients report difficulty obtaining specific estrogen patches, federal officials deny an imminent nationwide shortage. Manufacturers have reportedly doubled their production output over the last year by increasing shifts and expanding total manufacturing capacity. ## Systemic Treatment Approach ACOG recommends that treatment decisions be made jointly between doctors and patients, considering individual medical histories. Ideally, hormone therapy should be initiated before age sixty or within ten years of menopause onset. This personalized approach ensures that the benefits of systemic hormone delivery are balanced against potential risks for each patient. ## Nonhormonal Medication Options For patients unable or unwilling to use systemic hormone therapy, new pharmaceutical alternatives are available. Medications like fezolinetant and elinzanetant specifically target the brain's temperature control center to block hot flashes. Additionally, certain antidepressants are now utilized to manage the intersection of vasomotor symptoms and depressive moods in perimenopausal and postmenopausal women. ## Integrative Behavioral Therapies Beyond pharmaceutical interventions, the updated guidance supports several non-drug approaches for symptom relief. Evidence-based methods include cognitive behavioral therapy, mindfulness practices, and clinical hypnosis. These techniques can be employed independently or alongside medication to address sleep disruption and mood changes, providing a comprehensive toolkit for women navigating the menopausal transition. ## Combating Medical Misinformation ACOG leadership warns that online misinformation regarding menopause treatments remains a significant barrier to effective care. Patients are encouraged to bypass unverified internet claims and consult directly with their OB-GYNs for evidence-based advice. The organization provides resources to help women distinguish between false claims and medically validated treatment options for their symptoms. ## Clinical Empowerment Shift The core message of the new guidance is that women should not accept untreated symptoms as an inevitable reality. With a wide array of hormonal and nonhormonal options now validated, the focus has shifted toward proactive management. This clinical evolution aims to improve the quality of life for millions experiencing menopause-related health issues. ## Sources covering this story - https://www.thehindu.com/sci-tech/health/theres-new-guidance-on-menopause-symptoms-like-hot-flashes-what-women-need-to-know/article71652471.ece — --- _Summary written by Brifing from the original reporting. Copyright in the original article belongs to its publisher; read the full piece at the link above._